Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis

Pharmacogenomics

Volumn 6, Issue 5, 2005, Pages 481-490

  Ranganathan, Prabha ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Etanercept; Infliximab; Pharmacogenomics; Rheumatoid arthritis; Tumor necrosis factor antagonists

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CYTOKINE; ETANERCEPT; FC RECEPTOR; HLA B ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 3; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; JOINT DESTRUCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; PATHOGENESIS; PATIENT SELECTION; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; PREDICTION; PROMOTER REGION; PROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; GENETIC SCREENING; HAPLOTYPES; HUMANS; MODELS, BIOLOGICAL; MULTICENTER STUDIES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23044452973     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.2217/14622416.6.5.481     Document Type: Review

References (45)

1. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286(5439), 487-491 (1999).
2. van Ede AE, Laan RF, Blom HJ et al.: The C677T mutation in the methyleneterrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum. 44(11), 2525-2530 (2001).
3. Black AJ, McLeod HL, Capell HA et al.: Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann. Intern. Med. 129, 716-718 (1998).
4. Grell M, Douni E, Wajant H et al.: The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 83, 793-802 (1995).
5. Bayley JP, Ottenhoff TH, Verweij CL: Is there a future for TNF promoter polymorphisms? Genes Immun. 5, 315-329 (2004).
6. Louis E, Franchimont D, Piron A et al.: Tumor necrosis factor (TNF) gene polymorphism influences TNF-α production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin. Exp. Immunol. 113, 401-406 (1998).
7. Tang GJ, Huang SL, Yen HW et al.: Tumor necrosis factor gene polymorphism and septic shock in surgical infection (see comment). Crit. Care Med. 28, 2733-2736 (2000).
8. Bouma G, Crusius JB, Oudkerk Pool M et al.: Secretion of tumor necrosis factor α and lymphotoxin α in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J. Immunol. 43, 456-463 (1996).
9. Allen RD: Polymorphism of the human TNF-α promoter-random variation or functional diversity? Mol. Immunol. 36, 1017-1027 (1999).
10. Knight JC, Keating BJ, Rockett KA, Kwiatkowski DP: In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading (see comment). Nature Genet. 33, 469-475 (2003).
11. Huizinga TW, Westendorp RG, Bollen EL et al.: TNF-α promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J. Neuroimmunol. 72, 149-153 (1997).
12. Fabris M, Di PE, D'Elia A et al.: Tumor necrosis factor-α gene polymorphism in severe and mild-moderate rheumatoid arthritis. J. Rheumatol. 29, 29-33 (2002).
13. Udalova IA, Nedospasov SA, Webb GC et al.: Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics 16, 180-186 (1993).
14. Cope AP, Aderka D, Doherty M et al.: Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 35, 1160-1169 (1992).
15. Morita C, Horiuchi T, Tsukamoto H et al.: Association of tumor necrosis factor receptor Type II polymorphism 196R with Systemic lupus erythematosus in the Japanese: molecular and functional analysis. Arthritis Rheum. 44(12), 2819-2827 (2001).
16. Santee SM, Owen-Schaub LB: Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization. J. Biol. Chem. 271, 21151-21159 (1996).
17. Bathon JM, Martin RW, FLeischmann RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis (see comment) (erratum appears in N. Engl. J. Med. 344[3], 240 [2001]). N Engl. J. Med. 343(22), 1586-1593 (2000).
18. Lipsky PE, van der Heijde DM, St Clair EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. AntiTumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group (see comment). N. Engl. J. Med. 343(22), 1594-1602 (2000).
19. Kuiper S, Joosten LA, Bendele AM et al.: Different roles of tumor necrosis factor α and interleukin-1 in murine streptococcal cell wall arthritis. Cytokine 10, 690-702 (1998).
20. Dinarello CA, Wolff SM: The role of interleukin-1 in disease (erratum appears in N. Engl. J. Med. 328[10], 744 [1993]). N. Engl. J. Med. 328, 106-113 (1993).
21. Bertolini DR, Nedwin GE, Bringman TS et al.: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature 319, 516-518 (1986).
22. Saklatvala J: Tumor necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322, 547-549 (1986).
23. Scallon BJ, Moore MA, Trinh H et al.: Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 7, 251-259 (1995).
24. Van den Brande JM, Braat H, van den Brink GR et al.: Infliximab but not etanercept induces apoptosis in lamina propria T lymphocytes from patients with Crohn's disease (see comment). Gastroenterology 124, 1774-1785 (2003).
25. Gudbrandsdottir S, Larsen R, Sorensen LK et al.: TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin. Exp. Rheum. 22, 118-124 (2004).
26. Buch MH, Conaghan PG, Quinn MA et al.: True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin α? Ann. Rheum. Dis. 63, 1344-1346 (2004).
27. van Vollenhoven R, Harju A, Brannemark S, Klareskog L: Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumor necrosis factor α blockers can make sense (see comment). Ann. Rheum. Dis. 62, 1195-1198 (2003).
28. Weinblatt ME, Kremer JM, Bankhurst AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate (see comment). N. Engl. J. Med. 340(4), 253-259 (1999).
29. Maini RN, Breedveld FC, Kalden JR et al.: Therapeutic efficacy of multiple intravenous infusions of antitumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis (see comment). Arthritis Rheum. 41, 1552-1563 (1998).
30. Keystone EC, Kavanaugh AF, Sharp JT et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human antitumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50, 1400-1411 (2004).
31. Wong JB: Cost-effectiveness of antitumor necrosis factor agents. Clin. Exp. Rheum. 22, S65-S70 (2004).
32. Mugnier B, Balandraud N, Darque A et al.: Polymorphism at position -308 of the tumor necrosis factor α gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum. 48, 1849-1852 (2003).
33. Barrera P, Joosten LA, den Broeder AA et al.: Effects of treatment with a fully human antitumor necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin-1 and TNF-α in patients with rheumatoid arthritis. Ann. Rheum. Dis. 60, 660-669 (2001).
34. Cuchacovich M, Ferreira L, Aliste M et al.: Tumor necrosis factor-α (TNF-α) levels and influence of -308 TNF-α promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand. J. Rheumatol. 33, 228-232 (2004).
35. Fabris M, Tolusso B, Di Poi E et al.: Tumor necrosis factor-α receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J. Rheumatol. 29(9), 1847-1850 (2002).
36. Padyukov L, Lampa J, Heimburger M et al.: Genetic markers for the efficacy of tumor necrosis factor blocking therapy in rheumatoid arthritis. Ann. Rheum. Dis. 62, 526-529 (2003).
37. Gregersen PK, Silver J, Winchester RJ: The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30, 1205-1213 (1987).
38. Waldron-Lynch F, Adams C, Amos C et al.: Tumor necrosis factor 5′ promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families. Genes Immun. 2, 82-87 (2001).
39. Mulcahy B, Waldron-Lynch F, McDermott MF et al.: Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. Am. J. Hum. Genet. 59, 676-683 (1996).
40. Martinez A, Salido M, Bonilla G et al.: Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients (see comment). Arthritis Rheum. 50(4), 1077-1082 (2004).
41. Criswell LA, Lum RF, Turner KN et al.: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 50, 2750-2756 (2004).
42. Anonymous: Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium (see comment). Nature 401, 921-923 (1999).
43. Walsh EC, Mather KA, Schaffner SF et al.: An integrated haplotype map of the human major histocompatibility complex. Am. J. Hum. Genet. 73, 580-590 (2003).
44. Miretti MM, Walsh EC, Ke X et al.: A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms. Am. J. Hum. Genet. 76, 634-646 (2005).
45. Newton JL, Harney SM, Timms AE et al.: Dissection of class III major histocompatibility complex haplotypes associated with rheumatoid arthritis. Arthritis Rheum. 50, 2122-2129 (2004).